Here are five notes:
1. Under the agreement, Valeant obtained the rights to develop and commercialize NER1006 in the United States and Canada.
2. NER1006 is a low-volume polyethylene glycol-based bowel preparation solution that Norgine developed to provide overall bowel cleansing, with an additional focus on the ascending colon in adults.
3. Valeant will file for U.S. regulatory approval for NER1006 in 2016. Norgine, a European company, has completed a Phase III clinical trial program for NER1006.
4. Norgine will manufacture and supply NER1006 for Valeant.
5. Financial terms of the agreement have not been disclosed.
More articles on GI/endoscopy:
5 most read GI/endoscopy stories: Aug. 1 — Aug. 5
EndoChoice launches the Lumos imaging software system: 4 takeaways
Dr. Farzana Rashid Hossain appointed to 1st Philadelphia Commission for Women — 4 thoughts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.